2020
IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression
Stein S, Henze L, Poch T, Carambia A, Krech T, Preti M, Schuran FA, Reich M, Keitel V, Fiorotto R, Strazzabosco M, Fischer L, Li J, Müller LM, Wagner J, Gagliani N, Herkel J, Schwinge D, Schramm C. IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. Journal Of Hepatology 2020, 74: 919-930. PMID: 33197512, PMCID: PMC8778963, DOI: 10.1016/j.jhep.2020.10.035.Peer-Reviewed Original ResearchConceptsIL-17A/FIL-17PD-L1T cellsOT-1Mouse modelAutoimmune cholestatic liver diseaseCell death ligand 1Cholangiocyte organoidsMajor histocompatibility complex IBile duct inflammationAntigen-specific CD8Bile duct injuryPD-L1 expressionDeath ligand 1Driver of inflammationTreatment of cholangitisCholestatic liver diseaseResponse of miceImportant protective effectDuct inflammationExperimental cholangitisDuct injuryAdoptive transferCytotoxic CD8
2019
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal Of Autoimmunity 2019, 105: 102328. PMID: 31548157, DOI: 10.1016/j.jaut.2019.102328.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisAnti-mitochondrial autoantibodiesBiochemical cholestasisBiliary cholangitisBiliary epitheliumUrsodeoxycholic acidPBC-specific anti-nuclear antibodiesBile acidsToxic hydrophobic bile acidsAutoimmune liver diseaseSecond-line treatmentFirst-line treatmentAnti-nuclear antibodiesReliable disease markersEarly disease stagesCholestatic biochemical profileNew therapeutic approachesHydrophobic bile acidsAutoimmune originSeronegative casesLiver histologyAutoimmune attackFemale preponderanceHistologic confirmationImmunologic pathways
2017
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine
Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M. Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2017, 1864: 1415-1422. PMID: 28844954, DOI: 10.1016/j.bbadis.2017.08.025.Peer-Reviewed Original ResearchConceptsClinical outcome indicatorsAutoimmune liver diseaseLiver diseaseMajor autoimmune liver diseasesTertiary clinical centersPrimary sclerosing cholangitisPrimary biliary cholangitisDifferent clinical outcomesNatural history studiesValue of careAutoimmune hepatitisClinical practice environmentJesus BanalesMarco MarzioniNicholas LaRussoPeter JansenSclerosing cholangitisBiliary cholangitisConsecutive patientsClinical outcomesMedian timeCare pathwayClinical centersClinical strategiesValue-based medicine